• Awareness

Eisai Buys Out Purdue Rights to End Collaboration

New Delhi, May 02, 2019: Eisai Co., Ltd. announces that its U.S. subsidiary Eisai Inc. has bought out Purdue Pharma…

• Hospitals

Eisai to Present Latest Data on Lemborexant and Perampanel at Annual American Academy of Neurology Meeting

New Delhi, April 25, 2019: Eisai Co., Ltd. has announced that the latest data on its dual orexin receptor antagonist…

• Latest

Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials Cambridge, March…

• Archives

Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia

New Delhi, March 14, 2019: Eisai Co., Ltd. and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue…

• Archives

Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study

Tokyo, February 17, 2019: Eisai Co., Ltd. and Purdue Pharma L.P. announced a six-month results from SUNRISE 2, a long-term Phase…

• Archives

Eisai Submits Application in Europe Seeking Approval for Fycompa as Treatment for Pediatric Patients With Epilepsy

New Delhi, Febraury 14, 2019:  Eisai Co., Ltd. announced today that it has submitted an application to the European Medicines Agency…

Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in China to CY Biotech

Tokyo, August 04, 2018: Eisai Co., Ltd. announced today that it has entered into an agreement to grant exclusive development…

• Extras

AbbVie and Eisai Announce the Launch of HUMIRA Pen, an Auto-Injector Formulation for Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA

Tokyo, June 24, 2018: AbbVie GK, Eisai Co., Ltd. and Eisai’s subsidiary for gastrointestinal diseases EA Pharma Co., Ltd.announced that the…